Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2013
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Doxorubicin; Ifosfamide
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Acronyms LIDOXIF
- 06 Jul 2013 Planned patient number added to 100 as reported by European Clinical Trials Database record.
- 06 Jun 2013 Status added to completed as reported by European Clinical Trials Database record.
- 05 Nov 2010 New trial record.